- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03981731
Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session (COHEC)
Management of Perioperative Anxiety by the Fixed Rate Guided Breathing Technique (Cardiac Coherence) Coupled With a Hypnosis Session, as Part of the Improved Pre-habilitation After Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The perioperative period is recognized as an anxiety-provoking period for patients. If for some patients, this anxiety is more or less manageable, for others, it is the major concern with regard to their intervention, fearing not to wake up, to remain in a coma. Consideration of this aspect is very important for patients who require surgery. It is also a concern for caregivers involved in the care of these patients, including anesthesiologists, surgeons and operating room staff.
For many years, pharmacological premedication, including benzodiazepines, has been the gold standard in the treatment of preoperative anxiety.
This systematic prescription is controversial in populations most exposed to side effects such as the elderly, patients with heart or respiratory diseases.
Surgery also seems to influence the impact of premedication. For example, abdominal surgery and breast surgery are associated with a higher risk of agitation upon awakening.
Mental preparation, based on simple explanations by the anaesthetist, is not enough to reduce patients' anxiety.
A recent study evaluated the perioperative experience of patients receiving or not receiving premedication. It shows that benzodiazepines are associated with cognitive impairment and delayed extubation in the elderly. In addition, it seems to have little effect on patient anxiety when compared to a placebo.
In this context of anxiety, an emotional regulation tool appears particularly relevant. Cardiac coherence" (CC) is a particular state of cardiac variability. This state is correlated with many physiological and psychological variables. It is possible to promote this state through different techniques. One of its practices, "fixed frequency guided breathing", seems relevant both in its principles and in its simplicity of implementation.
This specific respiratory mode permits to rebalance the sympathetic - parasympathetic balance of the autonomic nervous system and reveals a state of calm vigilance. This simple, well-coded respiratory psychophysiological practice is widely used in many applications, such as for the most caricatural ones, the management of difficult situations where stress is a central element such as decision-making among fighter pilots on mission, in national education to improve academic learning (especially among anxious students) and also more generally in stress and anxiety management.
This technique induces a refocusing of emotions by regulating the SNA and therefore a better regulation of the hormones involved in the emotional cascade.
This practice has several advantages:
- it is psychophysiological (psychocorporeal) and widely described in the scientific literature in several indications
- it is completely free of charge and immediately accessible to the patient, regardless of time and place
- it can be used at other anxiety-inducing times (e.g., imaging or biopsy tests)
- it allows total patient autonomy, offering self-management of anxiety and independence from the presence of a third party
- it can approach a hypnotic model by focusing and absorbing what it can induce on breathing, and thus share some of its benefits
- It does not have any adverse effects. The major difficulty of this technique is the adherence and regularity of the practice. The optimal effect is dependent on regular training.
To improve this adherence, an audio tape will be put online, read in a hypnotic tone, which will aim to explain respiratory physiology, the benefits of oxygenation on cells and metabolism; this will have the effect of understanding the interest and utility of this exercise and will contribute to induce a feeling of relaxation and well-being.
This study will be a study of feasibility about a program based on the cardiac coherence technique in a context of perioperative anxiety.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hérault
-
Montpellier, Hérault, France, 34298
- Institut Régional du Cancer de Montpellier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Surgery for breast or gynaecological cancer requiring scheduled hospitalization for up to 3 days
- Signing of informed consent before any specific procedure in the study
- Patient affiliated to a social security system
Exclusion Criteria:
- Patients undergoing outpatient surgery for their cancer will not be included
- Natural bradycardia (50 beats per minute)
- Patient taking β-blockers, digoxin, flecaine, isoptin, cordarone, diltiazem
- Cardiac arrhythmias
- Severe heart failure with ventricular ejection fraction < 40%
- Uncontrolled chronic pain
- Patients whose medical or psychological conditions do not allow them to complete the study or sign the consent
- Patient does not understand the French language
- Deaf and/or dumb patient
- Adult patient under guardianship or curatorship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cardiac coherence
|
An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape. 3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation. - The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who have enrolled in the pre-habilitation program
Time Frame: 7 days
|
A patient will be considered to have optimally adhered to the program if she performs at least 2/3 of the proposed cardiac coherence sessions (that represents 67% of the total number of sessions), that is, at least 14 sessions over the 7 days preceding the surgery.
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The preoperative anxiety score by using the Amsterdam Preoperative Anxiety and Information Scale (APAIS)
Time Frame: 7 days
|
The anxiety scale consists of six items, each of which could be scored from 1 to 5 with the end poles "not at all" (1) and "extremely" (5).
The score of the anxiety scale is the sum of these four questions, with a scoring range from 6 to 30.
|
7 days
|
Patient's satisfaction with perioperative period by using "Evaluation of the Vecu of General Anesthesia" questionnaire (EVAN-G)
Time Frame: 48 hours
|
The validated EVAN-G questionnaire includes 26 questions whose results are grouped together to define 6 "dimensions": Attention Focus, Information, Privacy, Pain, Discomfort and Wait Times.
From these scores, an overall satisfaction score is calculated (average of all scores).
For each of the scores: the higher the score, the higher the satisfaction.
For each dimension, scores were reduced on a scale from 0 to 100.
The higher the score, the higher the perceived quality of the experience.
The total score was the sum of the scores of the six dimensions reduced to 100.
|
48 hours
|
Measurement of the Postoperative Quality of Recovery (QoR)
Time Frame: 10 days
|
The quality of postoperative functional recovery will be assessed by the QoR-15 questionnaire, which assesses five dimensions of recovery (physical comfort ; emotional state ; physical independence ; physiological support ; and pain).
Each item was rated on a ten-point Likert scale: none of the time, some of the time, usually, most of the time, and all the time.
The total score on the QoR-15 ranges from 0 (poorest quality of recovery) to 150 (best quality of recovery).
|
10 days
|
Measurement of anxiety level by using a visual analogue scale
Time Frame: 7 days
|
It's a visual scale from 0 (no anxiety) to 100 (highest anxiety)
|
7 days
|
Measurement of wake-up quality by using a visual analogue scale
Time Frame: 1 day
|
It's a visual scale from 0 (best wake-up) to 100 (worst wake-up)
|
1 day
|
Measurement of post-operative pain by using a visual analogue scale
Time Frame: 1 day
|
It's a visual scale from 0 (no pain) to 100 (highest pain)
|
1 day
|
Measurement of post-operative fatigue by using a visual analogue scale
Time Frame: 1 day
|
It's a visual scale from 0 (no fatigue) to 100 (highest fatigue)
|
1 day
|
Measurement of comfort and satisfaction with care by using a visual analogue scale
Time Frame: 1 day
|
It's a visual scale from 0 (ideal care) to 100 worst care)
|
1 day
|
Number of patients taking anesthetic drugs at induction of anaesthesia
Time Frame: 1 day
|
1 day
|
|
Number of patients taking anesthetic drugs during the post-interventional monitoring
Time Frame: 1 day
|
1 day
|
|
Number of patients taking morphine in recovery room
Time Frame: 1 day
|
1 day
|
|
Number of patients taking setrons (nausea and vomiting medication)
Time Frame: 1 day
|
1 day
|
|
Rate of patients that consider continuing the program of cardiac coherence
Time Frame: 1 day
|
1 day
|
|
Rate of patients willing to recommend the technique
Time Frame: 1 day
|
1 day
|
|
Number of days of hospitalization
Time Frame: 1 month
|
1 month
|
|
Number of patients taking morphine in peroperative
Time Frame: 1 day
|
1 day
|
|
Measurement of pain at inclusion by using a visual analogue scale
Time Frame: 1 day
|
It's a visual scale from 0 (no pain) to 100 (highest pain)
|
1 day
|
The recruitment rate (proportion of patients consenting to participate in the study among eligible patients at the screening) and reasons for refusal.
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
Investigators
- Study Chair: Jibba AMRAOUI, MD, Institut Régional du Cancer de Montpellier
Publications and helpful links
General Publications
- Lepouse C, Lautner CA, Liu L, Gomis P, Leon A. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth. 2006 Jun;96(6):747-53. doi: 10.1093/bja/ael094. Epub 2006 May 2.
- Van den Bosch JE, Moons KG, Bonsel GJ, Kalkman CJ. Does measurement of preoperative anxiety have added value for predicting postoperative nausea and vomiting? Anesth Analg. 2005 May;100(5):1525-1532. doi: 10.1213/01.ANE.0000149325.20542.D4.
- Pekcan M, Celebioglu B, Demir B, Saricaoglu F, Hascelik G, Yukselen MA, Basgul E, Aypar U. The effect of premedication on preoperative anxiety. Middle East J Anaesthesiol. 2005 Jun;18(2):421-33.
- Munoz HR, Dagnino JA, Rufs JA, Bugedo GJ. Benzodiazepine premedication causes hypoxemia during spinal anesthesia in geriatric patients. Reg Anesth. 1992 May-Jun;17(3):139-42.
- Agelink MW, Majewski TB, Andrich J, Mueck-Weymann M. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med. 2002 May;30(5):997-1006. doi: 10.1097/00003246-200205000-00008.
- McCraty R, Atkinson M, Tiller WA, Rein G, Watkins AD. The effects of emotions on short-term power spectrum analysis of heart rate variability. Am J Cardiol. 1995 Nov 15;76(14):1089-93. doi: 10.1016/s0002-9149(99)80309-9. Erratum In: Am J Cardiol 1996 Feb 1;77(4):330.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PROICM 2019-06 COH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Cardiac coherence
-
Centre Hospitalier Universitaire de la RéunionNot yet recruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingPost-traumatic Stress DisorderRéunion
-
Centre Hospitalier Universitaire de la RéunionUnknownHematologic Diseases | Cancer | Physical Activity
-
Institut du Cancer de Montpellier - Val d'AurelleRecruiting
-
University Hospital, ToulouseRecruiting
-
Institut de Recherche Biomedicale des ArmeesCompletedSchizophrenia
-
Centre Hospitalier Universitaire DijonTerminatedHigh Cardiovascular Risk Patients | Low Cardiovascular Risk PatientsFrance
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingPseudomyxoma Peritonei | Peritoneal Carcinomatosis | Mesothelioma PeritoneumFrance
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; King's College Hospital NHS TrustRecruitingCoronary Artery Disease | ST Elevation Myocardial Infarction | Ischemic Heart DiseaseUnited Kingdom